Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 3
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Olaparib Combined with Abiraterone versus Olaparib Monotherapy for Patients with Metastatic Castration-resistant Prostate Cancer Progressing after Abiraterone and Harboring DNA Damage Repair Deficiency: A Multicenter Real-world Study.
Xie J, Guo H, Dong B, Chen W, Jin C, Xu Q, Ding L, Liu W, Dong S, Zhao T, Yu Y, Guo C, Yao X, Peng B, Yang B. Xie J, et al. Among authors: guo h. Eur Urol Oncol. 2024 Mar 7:S2588-9311(24)00050-6. doi: 10.1016/j.euo.2024.02.005. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38458891
Concordance and Clinical Significance of Genomic Alterations in Progressive Tumor Tissue and Matched Circulating Tumor DNA in Aggressive-variant Prostate Cancer.
Wang R, Xu Q, Guo H, Yang G, Zhang J, Wang H, Xu T, Guo C, Yuan J, He Y, Zhang X, Fu H, Xu G, Zhao B, Xie J, Zhao T, Huang L, Zhang J, Peng B, Yao X, Yang B. Wang R, et al. Among authors: guo h. Cancer Res Commun. 2023 Nov 3;3(11):2221-2232. doi: 10.1158/2767-9764.CRC-23-0175. Cancer Res Commun. 2023. PMID: 37877742 Free PMC article.
Sustained complete response to first-line immunochemotherapy for highly aggressive TP53/MDM2-mutated upper tract urothelial carcinoma with ERBB2 mutations, luminal immune-infiltrated contexture, and non-mesenchymal state: a case report and literature review.
Xu T, Guo H, Xie J, He Y, Che J, Peng B, Yang B, Yao X. Xu T, et al. Among authors: guo h. Front Oncol. 2023 Jun 23;13:1119343. doi: 10.3389/fonc.2023.1119343. eCollection 2023. Front Oncol. 2023. PMID: 37427135 Free PMC article.